代谢综合征:风险因素和分子药物点
Rishabh Chalotra1, Aniket Gupta1, Thakur Gurjeet Singh2
1Laboratory of Neuroendocrinology and Metabolic Disorders, Department of Pharmacology, Central University of Punjab, Bathinda, India.
代谢综合征 (MetS) 影响全球数百万人,缺乏向治疗. 本次审查确定了十个关键的分子标,用于开发更安全的单药疗法,以有效管理MetS.
科学领域:
- 代谢障碍及其分子基础.
- 药理学研究和治疗目标的识别.
背景情况:
- 代谢综合征 (MetS) 是一种疾病集群,包括肥胖,高血糖,低HDL,高三糖血,高血压等.
- 影响全球人口的14-34%,MetS显著增加了动脉样硬化,糖尿病和其他慢性疾病的风险.
- 目前的管理依赖于多疗法和生活方式的改变,造成药物相互作用和慢性药物使用的风险.
研究的目的:
- 确定和分析十个关键的分子标,以全面管理代谢综合征 (MetS).
- 探索开发一种单一的向性药物治疗方法的潜在途径.
- 为了解决对MetS治疗更安全,更具体的治疗方法的需求.
主要方法:
- 文献综述和对MetS病变发生现有研究的分析.
- 识别和评估涉及到MetS开发的分子标.
- 综合信息以突出潜在的治疗策略.
主要成果:
- 已经确定并分析了10个关键的分子标,涉及到MetS病原体的产生.
- 这些目标代表了新药开发的潜在候选人.
- 这些发现支持对MetS进行向性药物治疗的追求.
结论:
- 对于代谢综合征的单一向药物治疗存在重大需求.
- 已确定的分子标为开发更安全,更有效的MetS治疗提供了有希望的途径.
- 对这些目标的进一步研究可能会改善患者的治疗结果,并减少治疗负担.
更多相关视频
10:31An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
相关概念视频
Coronary Artery Disease I: Introduction
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...
Oral Hypoglycemic Agents: Biguanides and Glitazones
